SCHEMBL14548914

SCHEMBL14548914

COC1CCCN(C(C)=O)C1

nearest known ligand 0.48

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
DPP4 P27487 1/20 0.43
DPP7 Q9UHL4 1/20 0.43
MTNR1A P48039 1/20 0.42
MTNR1B P49286 1/20 0.42
PDE4B Q07343 1/20 0.42
CYP4A11 Q02928 2/20 0.41
CYP4F2 P78329 1/20 0.41
ALDH1A1 P00352 1/20 0.40
MAPK1 P28482 1/20 0.40
VNN1 O95497 1/20 0.40
NAMPT P43490 1/20 0.39
NPC1 O15118 2/20 0.37
RAB9A P51151 2/20 0.37
GRM5 P41594 1/20 0.37
CHEK2 O96017 1/20 0.37
CYP1A2 P05177 1/20 0.37
CYP11B2 P19099 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6044667 0.88 PDE4B (0.40) MTNR1AMTNR1BPDE4BVNN1NAMPT
SCHEMBL2666756 0.88 PDE4B (0.40) MTNR1AMTNR1BPDE4BVNN1NAMPT
SCHEMBL17642630 0.88 PDE4B (0.40) MTNR1AMTNR1BPDE4BVNN1NAMPT
SCHEMBL1936718 0.85 DPP4 (0.43) DPP4DPP7ALDH1A1VNN1NPC1
SCHEMBL4472161 0.85 DPP4 (0.43) DPP4DPP7ALDH1A1VNN1NPC1
SCHEMBL4467851 0.85 DPP4 (0.43) DPP4DPP7ALDH1A1VNN1NPC1
SCHEMBL23581420 0.83 DPP4 (0.45) DPP4DPP7PDE4BALDH1A1MAPK1
SCHEMBL791935 0.83 PDE4B (0.43) DPP4DPP7PDE4BVNN1NPC1
SCHEMBL426886 0.83 DPP4 (0.42) DPP4DPP7ALDH1A1VNN1NPC1
SCHEMBL13910098 0.83 SMN1; SMN2 (0.41) MTNR1AMTNR1BPDE4BCYP4A11CYP4F2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230365605-A1 BICYCLIC HETEROARYL COMPOUNDS AND USES THEREOF WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT 2023-11-16 US disclosed
EP-3262036-B1 THERAPEUTIC PYRIDAZINE COMPOUNDS AND USES THEREOF GENENTECH INC (US) 2023-09-13 EP disclosed
WO-2023006097-A1 BIFUNCTIONAL CHIMERIC HETEROCYCLIC COMPOUND AND USE THEREOF AS ANDROGEN RECEPTOR DEGRADER 海创药业股份有限公司 2023-02-02 WO disclosed
US-9120774-B2 Novobiocin analogues having modified sugar moieties UNIVERSITY OF KANSAS (US) 2015-09-01 US disclosed
EP-2417140-B1 INHIBITORS OF HIV REPLICATION BOEHRINGER INGELHEIM INT (DE) 2014-11-26 EP disclosed
EP-2543390-A1 Pharmaceutical composition Kyowa Hakko Kirin Co., Ltd. (JP) 2013-01-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230365605-A1 BICYCLIC HETEROARYL COMPOUNDS AND USES THEREOF SOST, SOS1, SOS2 DPP4 2835/4885DPP7 2590/4885MTNR1A 915/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.